• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型强心剂DPN 205 - 734的药理作用

Pharmacological actions of DPN 205-734, a novel cardiotonic agent.

作者信息

Salzmann R, Scholtysik G, Markstein R, Bormann G

机构信息

Cardiovascular Unit of Preclinical Research, Sandoz Ltd., Basle, Switzerland.

出版信息

J Cardiovasc Pharmacol. 1988 Oct;12(4):451-60. doi: 10.1097/00005344-198810000-00011.

DOI:10.1097/00005344-198810000-00011
PMID:2465446
Abstract

DPN 205-734 [5-(4-cyanophenyl)-1,2-dihydro-6-methyl-2-oxopyridin-3-carbo nitrile] was investigated in vitro in Langendorff rabbit hearts, guinea pig and rabbit papillary muscles, and rat myocardium and in vivo in anesthetized and unanesthetized dogs, pithed open-chest cats, anesthetized rats, and cardiomyopathic hamsters. In vitro, this substance caused a concentration-dependent positive inotropic effect. Left ventricular dP/dtmax was increased in anesthetized dogs after intravenous injection of 0.02 and 0.2 mg/kg (35 +/- 10 and 130 +/- 13%, respectively) and in unanesthetized dogs after oral doses of 0.05-0.5 mg/kg (15 +/- 2 to 71 +/- 14%). DPN 205-734 lowered blood pressure and total peripheral resistance in several experimental models, indicating an afterload-reducing effect. It induced moderate tachycardia. The positive inotropic effect is not explainable by beta-stimulation as shown in pithed open-chest cats pretreated with propranolol. A phosphodiesterase-inhibiting activity (IC50 = 35.5 microM), measured in rat myocardium, may be primarily responsible for the positive inotropic action. In guinea pig papillary muscles partially depolarized with 22 mM K+, DPN 205-734 in a concentration of 1 microM restored slow action potentials, which were then blocked by carbachol. These actions can be explained by the increase in cardiac cyclic AMP level due to a phosphodiesterase-inhibiting effect. In rabbit papillary muscles the positive inotropic effect of DPN 205-734 (100 microM) was only moderately inhibited by carbachol (3 microM), suggesting an additional mechanism.

摘要

DPN 205 - 734 [5 - (4 - 氰基苯基)-1,2 - 二氢 - 6 - 甲基 - 2 - 氧代吡啶 - 3 - 甲腈] 在离体的Langendorff兔心脏、豚鼠和兔乳头肌以及大鼠心肌中进行了研究,并且在活体的麻醉和未麻醉犬、脊髓横断开胸猫、麻醉大鼠和心肌病仓鼠中进行了研究。在体外,该物质引起浓度依赖性正性肌力作用。静脉注射0.02和0.2mg/kg后,麻醉犬的左心室dP/dtmax增加(分别为35±10%和130±13%),口服0.05 - 0.5mg/kg后,未麻醉犬的左心室dP/dtmax增加(15±2%至71±14%)。DPN 205 - 734在多个实验模型中降低血压和总外周阻力,表明有减轻后负荷的作用。它引起中度心动过速。如用普萘洛尔预处理的脊髓横断开胸猫所示,正性肌力作用不能用β - 刺激来解释。在大鼠心肌中测得的磷酸二酯酶抑制活性(IC50 = 35.5μM)可能是正性肌力作用的主要原因。在22mM K⁺使部分去极化的豚鼠乳头肌中,1μM浓度的DPN 205 - 734恢复了慢动作电位,随后被卡巴胆碱阻断。这些作用可以用磷酸二酯酶抑制作用导致的心脏环磷酸腺苷水平升高来解释。在兔乳头肌中,3μM卡巴胆碱仅适度抑制了100μM DPN 205 - 734的正性肌力作用,提示存在其他机制。

相似文献

1
Pharmacological actions of DPN 205-734, a novel cardiotonic agent.新型强心剂DPN 205 - 734的药理作用
J Cardiovasc Pharmacol. 1988 Oct;12(4):451-60. doi: 10.1097/00005344-198810000-00011.
2
Pharmacological actions of APP 201-533, a novel cardiotonic agent.新型强心剂APP 201 - 533的药理作用
J Cardiovasc Pharmacol. 1985 May-Jun;7(3):588-96. doi: 10.1097/00005344-198505000-00027.
3
Cardiovascular actions of DPI 201-106, a novel cardiotonic agent.新型强心剂DPI 201-106的心血管作用
J Cardiovasc Pharmacol. 1986 Sep-Oct;8(5):1035-43. doi: 10.1097/00005344-198609000-00023.
4
Cardiovascular effects of the new cardiotonic agent 1,2-dihydro-6-methyl-2-oxo-5-(imidazo[1,2-a]pyridin-6-yl)-3-pyridine carbonitrile hydrochloride monohydrate. 1st communication: studies on isolated guinea pig cardiac muscles.新型强心剂盐酸一水合 1,2 - 二氢 - 6 - 甲基 - 2 - 氧代 - 5 -(咪唑并[1,2 - a]吡啶 - 6 - 基)- 3 - 吡啶甲腈的心血管效应。首次通讯:对豚鼠离体心肌的研究
Arzneimittelforschung. 1989 Jan;39(1):33-7.
5
Pharmacological and biochemical effects of the cardiotonic agent Org10325 in isolated cardiac and vascular tissue preparations.强心剂Org10325在离体心脏和血管组织制剂中的药理和生化作用。
Br J Pharmacol. 1990 Aug;100(4):735-42. doi: 10.1111/j.1476-5381.1990.tb14084.x.
6
Positive inotropic and electrophysiological effects of APP 201-533 can be explained by an increase of cardiac cyclic AMP.APP 201 - 533的正性肌力和电生理效应可通过心脏环磷酸腺苷(cAMP)的增加来解释。
J Cardiovasc Pharmacol. 1985 May-Jun;7(3):597-603. doi: 10.1097/00005344-198505000-00028.
7
Characterization of MS-857, a new and potent cardiotonic agent, in isolated mammalian cardiac muscles.新型强效强心剂MS - 857在离体哺乳动物心肌中的特性研究
J Cardiovasc Pharmacol. 1989 Nov;14(5):790-7. doi: 10.1097/00005344-198911000-00017.
8
Lack of stereoselectivity in the inotropic and phosphodiesterase inhibitory effects of saterinone enantiomers.沙替利酮对映体在正性肌力和磷酸二酯酶抑制作用方面缺乏立体选择性。
Arzneimittelforschung. 1989 Nov;39(11):1384-92.
9
Effects of a cardiotonic quinolinone derivative Y-20487 on the isoproterenol-induced positive inotropic action and cyclic AMP accumulation in rat ventricular myocardium: comparison with rolipram, Ro 20-1724, milrinone, and isobutylmethylxanthine.强心喹啉酮衍生物Y-20487对异丙肾上腺素诱导的大鼠心室肌正性肌力作用及环磷酸腺苷积累的影响:与咯利普兰、Ro 20-1724、米力农和异丁基甲基黄嘌呤的比较。
J Cardiovasc Pharmacol. 1992;20(5):715-22.
10
Positive inotropic activity of 5-amino-6-cyano-1,3-dimethyl-1,2,3,4-tetrahydropyrido[2,3-d]pyrim idine-2,4-dione in cardiac muscle from guinea-pig and man. Part 6: Compounds with positive inotropic activity.5-氨基-6-氰基-1,3-二甲基-1,2,3,4-四氢吡啶并[2,3-d]嘧啶-2,4-二酮对豚鼠和人心肌的正性肌力活性。第6部分:具有正性肌力活性的化合物。
Pharmazie. 1993 Jul;48(7):537-41.

引用本文的文献

1
Pharmacological actions of SDZ 218-135, a novel positive inotropic agent.新型正性肌力药物SDZ 218 - 135的药理作用
Cardiovasc Drugs Ther. 1994 Apr;8(2):235-44. doi: 10.1007/BF00877332.
2
Actions of the phosphodiesterase inhibitor zardaverine on guinea-pig ventricular muscle.磷酸二酯酶抑制剂扎达维林对豚鼠心室肌的作用。
Naunyn Schmiedebergs Arch Pharmacol. 1990 Aug;342(2):221-7. doi: 10.1007/BF00166968.